JNJ-7706621

JNJ-7706621

Catalog Number:
L002369027APE
Mfr. No.:
APE-A4115
Price:
$306
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDK) and Aurora kinases that potently inhibits CDK1, CDK2, CDK3, CDK4, CDK6, Aurora-A, and Aurora-B in vitro with 50% inhibition concentration IC50 values of 0.009, 0.004, 0.003, 0.058, 0.253, 0.175, 0.011 and 0.015 μmol/L respectively. JNJ-7706621 selectively inhibits proliferation of both normal human cells and tumor cells of various origins, where the efficacy of JNJ-7706621 is 10-fold greater in tumor cells (IC50 range of 0.112 to 0.514 μmol/L) than normal cells (IC50 range of 3.67 to 5.42 μmol/L). JNJ-7706621 has been found to induce apoptosis, suppress colony formation and inhibit cell growth regardless of p53, retinoblastoma or P-glycoprotein status in human cancer cells.

      • Properties
        • Alternative Name
          JNJ7706621, JNJ 7706621; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
          CAS Number
          443797-96-4
          Molecular Formula
          C15H12F2N6O3S
          Molecular Weight
          394.36
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          insoluble in EtOH; insoluble in H2O; ≥19.7 mg/mL in DMSO
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Zhong S, Wu B, et al. "Identification of Driver Genes and Key Pathways of Glioblastoma Shows JNJ-7706621 as a Novel Antiglioblastoma Drug." World Neurosurg. 2018 Jan;109:e329-e342. PMID:28989042

    We Also Recommend

    AT9283

    $260

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.